In the SOLOIST-WHF study which included patients hospitalized due to worsening HF, the administration of sotagliflozin, which is a both SGLT2 and 1 inhibitor, either immediately prior to or shortly following discharge, resulted in a significant decrease in death from CV causes and hospitalizations and urgent visits for HF (HR 0.67; 95% CI 0.52-0.85; P < 0.001).6 This evidence concerns the gene SLC5A2 and hydrops fetalis.